Mark A. Socinski, MD

NCT03088813

RESILIENT: A Randomized, Open Label Phase 3 Study of Irinotecan Liposome Injection (ONIVYDE®) versus Topotecan in Patients with Small Cell Lung Cancer Who Have Progressed on or after Platinum-based First-Line Therapy

This study will take place in 2 parts (Part 1 and Part 2). The purpose of Part 1 is to find out what is the best dose of irinotecan liposome injection to be used in Part 2 of the study. Once the best dose is found, Part 1 will ...

NCT03014648

A phase II clinical trial evaluating the efficacy of atezolizumab in advanced non-small cell lung cancer (NSCLC) patients previously treated with PD-1-directed therapy

The main goal of this research study is to determine if atezolizumab prevents your lung cancer from growing and for how long. If you decide to participate in this study, you will be assigned to a group based on how well your ca ...

NCT03833154

A Phase III, Randomized, Placebo-=controlled, Double-blind, Multi-center, International Study of Durvalumab Following Stereotactic Body Radiation Therapy (SBRT) for the Treatment of Patients with unresected Stage I/II, lymph-node negative Non-small Cell Lung Cancer (PACIFIC-4/RTOG-3515)

AstraZeneca AB is doing this research to find out if the medication called durvalumab will work and be safe for the treatment of patients with Stage I/II Non Small Cell Lung Cancer following stereotactic body radiation therapy. ...

NCT03175224

Phase 1/2 Multicenter Study of the Safety, Pharmacokinetics, and Preliminary Efficacy of APL-101 in Subjects with Non-Small Cell Lung Cancer with c-Met EXON 14 skip mutations and c-Met Dysregulation Advance Solid Tumors

The purpose of this study is to evaluate the safety and effectiveness of APL-101, a c-Met inhibitor, for the treatment of advanced c-Met expressing solid tumors, including NSCLC, and to find the best dose. How quickly APL-101 i ...

NCT03906331

A Multi-Center Expanded Access Program (EAP) for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors with Rearranged During Transfection (RET) Activation (LIBRETTO-201)

LOXO-292 is an oral investigational drug that may treat your cancer. LOXO-292 is a tyrosine kinase inhibitor designed to inhibit a protein called RET. As a result, LOXO-292 might be more effective in tumors with abnormalities i ...

NCT03611738

Phase I Study of Ceritinib Plus Docetaxel in ALK-Negative, EGFR WT Advanced NSCLC

This study is currently enrolling.

The main purpose of this study is to find out what effects (good and bad) ceritinib (Zykadia) used in combination with docetaxel (Taxotere) will have on you and your cancer.

NCT04036682

A Phase 1/2a, Open-Label, Multi-Center Trial to Assess Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of CLN-081 in Patients with Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations

This study has 3 parts; Phase 1 Dose Escalation, Phase 1 Dose Expansion, and Phase 2a Dose Expansion. Phase 1 Dose Escalation: the main aim of this part of the study is to find a maximum tolerated dose for CLN-081. This will be ...

NCT03786692

TH-138: Phase II Randomized Trial of Carboplatin = Pemetrexed + Bevaciumab, with or without Atezolizumab in Stage IV Non-Squamous NSCLC Patients who Harbor a Sensitizing EGFR Mutation or have never Smoked

This study is currently enrolling.

The purpose of this research study is to determine if the combination therapy of carboplatin, pemetrexed, bevacizumab (Avastin) and atezolizumab (Tecentriq) is better at controlling disease progression in never smoker and sensi ...

NCT03854227

A Phase 1 Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Escalating Doses of PF-069399999 (PRMT5 Inhibitor) in Participants with Advanced or Metastatic Non-small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma, Esophageal Cancer, Endometrial Cancer, Cervical Cancer and Bladder Cancer.

The purpose of this study is to learn about the effects of the study drug PF_06939999 (study drug) taken alone or in combination with docetaxel.

NCT04746924

A Phase 3, Randomized, Double-Blind Study of BGB-A1217, an Anti-TIGIT Antibody, in Combination With Tislelizumab Compared to Pembrolizumab in Patients With Previously Untreated, PD-L1-Selected, and Locally Advanced, Unresectable, or Metastatic Non-Small Cell Lung Cancer.

This study is currently enrolling.

This study will look at the efficacy and safety of combined treatment with 2 anticancer drugs, which are called tislelizumab (also known as BGB-A317) and BGB-A1217 compared to treatment with pembrolizumab and saline (a mix of s ...

NCT03631199

A randomized, double-blind, placebo-controlled, phase III study evaluating the efficacy and safety of pembrolizumab plus platinum-based doublet chemotherapy with or without canakinumab as first line therapy for locally advanced or metastatic non-squamous and squamous non-small cell lung cancer subjects (CANOPY-1)

The purpose of the study is to evaluate how safe and effective canakinumab in combination with other drugs (pembrolizumab and platinum-based doublet chemotherapy) already commonly used to treat lung cancer is. The purpose is al ...

NCT04613596

A Phase 2 Trial of MRTX849 in Combination with Pembrolizumab in Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation

This study is currently enrolling.

The main purpose of this study is to evaluate the clinical activity of MRTX849 administered in combination with pembrolizumab in the first-line treatment setting to subjects with Advanced Non-Small Cell Lung Cancer (NSCLC) with ...

NCT04140526

Safety, Pharmacokinetics (PK), and Efficacy of ONC-392 as a Single Agent and
in Combination with Pembrolizumab in Advanced Solid Tumors and NSCLC: An Open-label Phase IA/IB Study.

This study is currently enrolling.

This is a research study to find out if an experimental drug called ONC-392 is safe and effective in cancer patients and how the drug is absorbed and processed in the body of patients with cancer. ONC-392 is an antibody drug th ...

Mark A. Socinski, MD

Overview

Articles

IMpower150 Final Exploratory Analyses for Atezolizumab Plus Bevacizumab and Chemotherapy in Key NSCLC Patient Subgroups With EGFR Mutations or Metastases in the Liver or Brain

['Poziotinib in Non-Small-Cell Lung Cancer Harboring', 'Exon 20 Insertion Mutations After Prior Therapies: ZENITH20-2 Trial.']

A phase 1b/2 study of PF-06747775 as monotherapy or in combination with Palbociclib in patients with epidermal growth factor receptor mutant advanced non-small cell lung cancer

Blood-based tumor mutational burden as a biomarker for atezolizumab in non-small cell lung cancer: the phase 2 B-F1RST trial

Poziotinib in Non-Small-Cell Lung Cancer Harboring HER2 Exon 20 Insertion Mutations After Prior Therapies: ZENITH20-2 Trial

Clinical efficacy of atezolizumab plus bevacizumab and chemotherapy in KRAS-mutated non-small cell lung cancer with STK11, KEAP1, or TP53 comutations: subgroup results from the phase III IMpower150 trial

Safety, tolerability and preliminary efficacy of poziotinib with twice daily strategy in EGFR/HER2 Exon 20 mutant non-small cell lung cancer

nab-Paclitaxel/Carboplatin in Vulnerable Populations With Advanced Non-Small Cell Lung Cancer: Pooled Analysis

CRESTONE: Clinical study of response to seribantumab in tumors with neuregulin-1 (NRG1) fusions-A phase II study of the anti-HER3 mAb for advanced or metastatic solid tumors (NCT04383210).

Nanoparticle Albumin-bound Paclitaxel Plus Carboplatin Induction Followed by Nanoparticle Albumin-bound Paclitaxel Maintenance in Squamous Non-Small-cell Lung Cancer ABOUND.sqm): A Phase III Randomized Clinical Trial

Education & Training

Education

Residency

Fellowship

Specialty

Board Certifications

Associated Clinical Trials

RESILIENT: A Randomized, Open Label Phase 3 Study of Irinotecan Liposome Injection (ONIVYDE®) versus Topotecan in Patients with Small Cell Lung Cancer Who Have Progressed on or after Platinum-based First-Line Therapy

A phase II clinical trial evaluating the efficacy of atezolizumab in advanced non-small cell lung cancer (NSCLC) patients previously treated with PD-1-directed therapy

A Phase III, Randomized, Placebo-=controlled, Double-blind, Multi-center, International Study of Durvalumab Following Stereotactic Body Radiation Therapy (SBRT) for the Treatment of Patients with unresected Stage I/II, lymph-node negative Non-small Cell Lung Cancer (PACIFIC-4/RTOG-3515)

Phase 1/2 Multicenter Study of the Safety, Pharmacokinetics, and Preliminary Efficacy of APL-101 in Subjects with Non-Small Cell Lung Cancer with c-Met EXON 14 skip mutations and c-Met Dysregulation Advance Solid Tumors

A Multi-Center Expanded Access Program (EAP) for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors with Rearranged During Transfection (RET) Activation (LIBRETTO-201)

Phase I Study of Ceritinib Plus Docetaxel in ALK-Negative, EGFR WT Advanced NSCLC

A Phase 1/2a, Open-Label, Multi-Center Trial to Assess Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of CLN-081 in Patients with Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations

TH-138: Phase II Randomized Trial of Carboplatin = Pemetrexed + Bevaciumab, with or without Atezolizumab in Stage IV Non-Squamous NSCLC Patients who Harbor a Sensitizing EGFR Mutation or have never Smoked

A Phase 3, Randomized, Double-Blind Study of BGB-A1217, an Anti-TIGIT Antibody, in Combination With Tislelizumab Compared to Pembrolizumab in Patients With Previously Untreated, PD-L1-Selected, and Locally Advanced, Unresectable, or Metastatic Non-Small Cell Lung Cancer.

A Phase 2 Trial of MRTX849 in Combination with Pembrolizumab in Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation

Safety, Pharmacokinetics (PK), and Efficacy of ONC-392 as a Single Agent and
in Combination with Pembrolizumab in Advanced Solid Tumors and NSCLC: An Open-label Phase IA/IB Study.

Explore

Institutes